A new study on GLP1s eye risk

GLP1.Guide Staff

21 Sep 2025 — 1 min read

One of the biggest emerging risks of using GLP1s has been the link between GLP1s and vision loss — whether via NAION or macular degeneration.

We’ve covered this before:

Some new research (a study, not a trial) has emerged with regards to the eye related risks of GLP1s, and the results are surprising — they’re not as negative as one would imagine.

The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:

Read the rest on Substack

Read more

Last week in GLP1 (2025/09/22)

Here’s what happened last week in the GLP1 ecosystem: 📊 Study: Wegovy pill shows 16.6% weight loss 📢 Eli Lilly says Orforglipron is even better than the Wegovy pill 📺 GLP1s in patch form? Not yet 📑 GLP1s could reduce all-cause mortality by up to 6% by 2045 ❓Bariatric surgery more effective

Last week in GLP1 (2025/09/15)

Here’s what happened last week in the GLP1 ecosystem: 🧑‍⚖️ Lawsuits over the negative side effects of GLP1s 🌐 The WHO is building a guideline for GLP1 use and requesting comments 🎭 Celebrity endorsements continue: Andy Cohen reveals use of GLP1s for weight management 🚨 GLP1 is now being used in SMS scams

Massive GLP1 use in Silicon Valley survey

We mostly hear of increased adoption of GLP1s in the mainstream — entertainers and public figures being quizzed on whether they use it or not, spectacular transformations for patients who have found a GLP1 that works for them, etc. Silicon Valley and those that like to experiment or “bio-hack” were very

An under-reported negative side effect: CVS

An under-reported negative side effect: CVS

Keeping track of negative side effects of GLP1s is just as important (if not more important) than keeping track of positive side effects. Cyclic Vomiting Syndrome is a *rare* negative side effect that doesn’t come up in the research very often, but after hearing anecdotal reports of this side